The workflow retrieves extensive functional and expression information such as protein function, subcellular localization, tissue-specific and disease-relevant expression data, and related disease annotations. This enables evaluation of target relevance in the biological context of interest.
For tractability insights, it collects rich druggability data comprising associated mechanisms of action (MOA), linked approved and investigational drugs with detailed activity profiles, and chemical probes validated for target modulation. It further aggregates compound bioactivity data by assay type, supporting ligand-based drug discovery and QSAR modeling.
Structure-based tractability is informed through retrieval of experimental 3D structures and ligand information from PDB. Additional small-molecule tractability scores and druggable family classifications come from Open Targets, delivering a multi-dimensional view of target feasibility.
Interactive visualizations summarize these data, enabling filtering and detailed exploration of targets’ clinical development status, drug-target interactions, chemical probe availability, compound activity breadth, and structural data quality. The workflow supports export of results for downstream analysis, making it a valuable tool for prioritizing targets to guide resource allocation in drug discovery projects.
To use this workflow in KNIME, download it from the below URL and open it in KNIME:
Download WorkflowDeploy, schedule, execute, and monitor your KNIME workflows locally, in the cloud or on-premises – with our brand new NodePit Runner.
Try NodePit Runner!Do you have feedback, questions, comments about NodePit, want to support this platform, or want your own nodes or workflows listed here as well? Do you think, the search results could be improved or something is missing? Then please get in touch! Alternatively, you can send us an email to mail@nodepit.com.
Please note that this is only about NodePit. We do not provide general support for KNIME — please use the KNIME forums instead.